Top-News

Foamix Pharmaceut News

Keine aktuellen Kursdaten verfügbar
WKN: A12BKW
ISIN: IL0011334385
US-Symbol: FOMX
Typ: Aktie

Foamix Pharmaceut News

09.03.20 - PR Newswire
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for ...
18.02.20 - PR Newswire
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea PR Newswire
06.02.20 - PR Newswire
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology PR Newswire
14.01.20 - PR Newswire
Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the ...
09.01.20 - PR Newswire
Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne AMZEEQ is the First ...
11.12.19 - PR Newswire
Lifshitz & Miller LLP Announces Investigation of Carolina Financial Corporation, Craft Brew Alliance, Inc., Foamix Pharmaceuticals Ltd., Grubhub Inc., Lipocine Inc., Pattern Energy Group, Inc., TD Ameritrade Holding Corporation, and William Lyon Homes
Lifshitz & Miller LLP Announces Investigation of Carolina Financial Corporation, Craft Brew Alliance, Inc., Foamix Pharmaceuticals Ltd., Grubhub Inc., Lipocine Inc., Pattern Energy ...
18.11.19 - PR Newswire
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam PR Newswire
15.11.19 - PR Newswire
URGENT NEWS: Monteverde & Associates PC Announces an Investigation of FOAMIX PHARMACEUTICALS LTD - FOMX
URGENT NEWS: Monteverde & Associates PC Announces an Investigation of FOAMIX PHARMACEUTICALS LTD - FOMX PR Newswire
12.11.19 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd. PR Newswire
04.11.19 - PR Newswire
Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology PR ...
17.10.19 - PR Newswire
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-​to-Severe Papulopustular Rosacea PDUFA Target ...
10.10.19 - PR Newswire
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference PR Newswire
05.08.19 - PR Newswire
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-​to-Severe Papulopustular Rosacea PR Newswire
14.09.17 - PR Newswire
OWC Pharma Issues Chairman's Letter to Shareholders
OWC Pharma Issues Chairman's Letter to Shareholders PR Newswire
03.08.17 - PR Newswire
Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101 Company validates clinical development pathway via FDA Type B Meeting PR ...
29.06.17 - PR Newswire
Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer PR Newswire
15.06.17 - PR Newswire
Foamix Pharmaceuticals to Present at the 2017 BIO International Convention
Foamix Pharmaceuticals to Present at the 2017 BIO International Convention PR Newswire
12.06.17 - PR Newswire
Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5% PR Newswire
01.06.17 - PR Newswire
Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference PR Newswire
09.05.17 - PR Newswire
Foamix Reports First Quarter 2017 Financial Results and Provides Business Update
Foamix Reports First Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am ...

Newssuche

Videos

newspaper
08:40 Uhr +5,90%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »